FINANCIAL STATEMENTS RYVU THERAPEUTICS S.A.

prepared for the year from 1 January 2024 to 31 December 2024

in accordance with International Financial Reporting Standards as approved by the European Union

It is the translation of Polish original document

Table of Contents

Notes to the Financial Statements

STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD FROM 1 JANUARY 2024 TO 31 DECEMBER 2024

	Note	Period ended 31/12/2024	Period ended 31/12/2023
		000' PLN	000' PLN
Continuing operations			
Sales revenue	5.1	77,968	46,860
Grant income	5.2	23,993	20,436
Total operating revenue		**101,961**	**67,296**
Amortization and depreciation		-10,496	-10,971
Consumption of materials and supplies		-19,580	-17,554
External services		-114,011	-67,225
Employee benefit expense	5.4	-69,578	-56,239
Valuation of the incentive program	28	-4,137	-8,313
Other expenses		-4,495	-3,806
Taxes and charges		-1,443	-932
Total operating expenses		**-223,738**	**-165,041**
Valuation of shares in Nodthera	13	-130	-3,572
Other operating revenue		85	697
Other operating expenses		-278	-328
Operating (Loss)		**-122,099**	**-100,948**
Financial revenue	7	15,977	13,833
Financial expenses	8	-5,016	-4,997
(Loss) before income tax		**-111,138**	**-92,112**
Income tax expense	9	-297	0
Net (loss) on continuing operations		**-111,435**	**-92,112**
NET (LOSS)		**-111,435**	**-92,112**
TOTAL (LOSS) FOR THE PERIOD		**-111,435**	**-92,112**
(Loss) per share			
(expressed in PLN per share)	10		
From continued operations:			
Basic		(4.8)	(4.0)
Diluted		(4.8)	(4.0)

The accompanying notes form an integral part of these financial statements.

STATEMENT OF FINANCIAL POSITION
PREPARED AS AT 31 DECEMBER 2024

	Note	Balance as at 31/12/2024	Balance as at 31/12/2023
		000' PLN	000' PLN
ASSETS			
Non-current assets			
Tangible fixed assets	11	70,234	76,517
Right-of-use assets	11	2,502	1,038
Intangible fixed assets	12	8,116	6,337
Financial assets-Shares in Nodthera	13	16,774	16,904
Other financial assets	16	19	17,480
Other non-financial assets	15	8,696	6,534
Total non-current assets		**106,341**	**124,809**
Current assets			
Inventory		1,210	2,118
Short-term receivables	17	35,776	32,837
Other financial assets	16	65,857	175,733
Other non-financial assets	15	9,520	9,766
Cash and other monetary assets	26	160,073	57,939
Total current assets		272,436	278,393
Total assets		**378,777**	**403,202**
EQUITY AND LIABILITIES			
Equity			
Share capital	18	9,248	9,248
Reserve capital	18	519,748	519,748
Own shares	18	0	0
Capital resulting from the split		-335,396	-335,396
Other reserve capitals	18	61,728	66,001
Retained earnings / Accumulated losses		-9	92,102
Net (Loss) for the period		-111,435	-92,112
Total equity		**143,884**	**259,592**
Long-term liabilities			
Bank loans	19	73,333	0
Lease liabilities		1,390	365
Retirement provision		276	432
Long term finance liabilities	20	9,228	8,854
Deferred revenues	24	16,783	23,250
Contract liabilities	24	25,955	41,006
Total long-term liabilities		**126,965**	**73,907**
Short-term liabilities			
Trade and other liabilities	21	35,748	27,433
Bank loans		292	127
Lease liabilities		499	414
Short-term finance liabilities	20	25,788	0
Employee benefit liabilities	23	9,890	10,197
Contract liabilities	24	29,902	25,305
Deferred income	24	5,809	6,227
Total short-term liabilities		**107,928**	**69,703**
Total liabilities		**234,893**	**143,610**
Total equity and liabilities		**378,777**	**403,202**

The accompanying notes form an integral part of these financial statements.

STATEMENT OF CHANGES IN EQUITY
FOR THE REPORTING PERIOD ENDED 31 DECEMBER 2024

	Note	Share capital	Share premium	Reserve capital paid up but not registered as at the balance sheet date	Own shares	Capital created as a result of spin-off	Other reserve capitals	Retained earnings / Accumulated losses	Net (Loss) for the period	Total
		000' PLN	000' PLN	000' PLN	000' PLN	000' PLN	000' PLN	000' PLN	000' PLN	000' PLN
Balance as at 1 January 2023		**7,342**	**279,063**	**242,591**	**0**	**-335,396**	**57,688**	**175,885**	**-83,782**	**343,390**
Net loss for the period		0	0	0	0	0	0	0	-92,112	**-92,112**
Issue of shares	18.5	1,906	240,685	-242,591	0	0	0	0	0	**0**
Creation of reserve capital as part of the incentive program	28	0	0	0	0	0	8,313	0	0	**8,313**
Allocation of the result from previous year		0	0	0	0	0	0	-83,782	83,782	**0**
Balance as at 31 December 2023		**9,248**	**519,748**	**0**	**0**	**-335,396**	**66,001**	**92,102**	**-92,112**	**259,592**
Net loss for the period		0	0	0	0	0	0	0	-111,435	**-111,435**
Creation of reserve capital as part of the incentive program	28	0	0	0	0	0	4,137	0	0	**4,137**
Subscription warrants valuation	18.3	0	0	0	0	0	24,228	0	0	**24,228**
Valuation of the put option resulting from the agreement with the EIB	18.3	0	0	0	0	0	-32,637	0	0	**-32,637**
Allocation of the result from previous year		0	0	0	0	0	0	-92,112	92,112	0
Balance as at 31 December 2024		**9,248**	**519,748**	**0**	**0**	**-335,396**	**61,728**	**-9**	**-111,435**	**143,884**

The accompanying notes form an integral part of these financial statements.

STATEMENT OF CASH FLOWS
FOR THE PERIOD FROM 1 JANUARY 2024 TO 31 DECEMBER 2024

	Note	Period ended 31/12/2024	Period ended 31/12/2023
		000' PLN	000' PLN
Cash flows from operating activities			
(Loss) for the period		**-111,435**	**-92,112**
Adjustments:			
Valuation of shares in Nodthera		130	3,572
Amortization and depreciation and impairment losses on fixed assets		10,496	10,971
Profits (losses) from exchange rate differences		-214	3,995
Interest and profit-sharing (dividends), net		-12,010	-5,016
Change in receivables		-2,940	-15,906
Change in inventories		909	-360
Change in short-term liabilities and provision excluding credits and loans	32	-9,749	9,907
Change in deferred income		-6,885	5,085
Change in other assets		-1,916	-13,001
Valuation of the incentive program	28	4,137	8,313
Net cash flows from operating activities		**-129,479**	**-84,550**
Cash flows from investing activities			
Acquisition of property, plant and equipment and intangible assets	11;12	-5,903	-8,579
Inflows/refunds from subsidies to fixed assets		0	535
Acquisition/Sale of other financial assets	16	127,337	-192,610
Interest received		15,731	5,112
Net cash flows from investing activities		**137,165**	**-195,541**
Cash flows from financing activities			
Issuance of series J shares		0	250,284
Costs of issuing series J shares		0	-7,693
Repayment of finance lease liabilities		-441	-1,041
Proceeds from EIB financing		94,491	127
Repayment of loans		165	-747
Interest paid		-6	-97
Net cash flows from financing activities		**94,209**	**240,833**
Net increase / (decrease) in cash and cash equivalents		101,895	-39,259
Cash and cash equivalents at the beginning of the period		57,939	101,917
The impact of changes in exchange rates on the balance of cash in foreign currencies		239	-4,720
Cash and cash equivalents at the end of the period	26	**160,073**	**57,939**

The accompanying notes form an integral part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS
PREPARED AS AT 31 DECEMBER 2024

1. General information

1.1. The company

Ryvu Therapeutics S.A. was established as a result of the transformation of Selvita Spółka z o.o. in a joint-stock company based on the Notarial Deed of August 20, 2010 prepared at the notary's office A. Deflorian, D. Jastrzębska-Kwiecień Spółka Cywilna (Rep. No. 3222/2010). The registered office of the company is in Poland, Cracow, Bobrzyńskiego Street 4. Currently, the Company is registered in the Register of Entrepreneurs of the National Court Register at the District Court for the city of Kraków - Śródmieście - XI Economic Department under the KRS number 0000367359.

Composition of the management and supervisory bodies as at the date of these financial statements:

Management Board:

Paweł Przewięźlikowski	-	President of the Management Board
Krzysztof Brzózka	-	Vice-President of the Management Board
Kamil Sitarz	-	Member of the Management Board
Hendrik Nogai	-	Member of the Management Board
Vatnak Vat-Ho	-	Member of the Management Board

Supervisory Board:

Piotr Romanowski	-	Chairman
Tadeusz Wesołowski	-	Vice- Chairman
Rafał Chwast	-	Member
Axel Glasmacher	-	Member
Thomas Turalski	-	Member
Scott Z. Fields	-	Member
Peter Smith		Member

As at December 31, 2024 the shareholder structure of the company is as follows:

	Registered office	Number of shares	Percentage interest in capital	Percentage share in voting rights
Paweł Przewięźlikowski	Poland	3,982,160	17.22%	27.54%
Bogusław Sieczkowski	Poland	825,348	3.57%	5.06%
Management Board + Board of Directors		527,266	2.28%	1.94%
Nationale Nederlanden OFE	Poland	1,389,036	6.01%	5.11%
TFI Allianz Polska S.A.	Poland	2,282,909	9.87%	8.40%
Allianz Polska OFE	Poland	2,132,540	9.22%	7.85%
Tadeusz Wesołowski (wraz z Augebit FIZ)	Poland	1,372,713	5.94%	5.05%
BioNTech SE	Germany	1,917,437	8.29%	7.06%
Other		8,690,739	37.60%	31.99%
Total		**23,120,148**	**100.00%**	**100.00%**

As of December 31, 2023, the shareholding structure of the Company was as follows:

	Registered office	Number of shares	Percentage interest in capital	Percentage share in voting rights
Paweł Przewięźlikowski	Polska	4,065,036	17.58%	27.84%
Bogusław Sieczkowski	Polska	825,348	3.57%	5.06%
Management Board + Board of Directors		539,766	2.33%	1.99%
Nationale Nederlanden OFE	Polska	1,900,000	8.22%	6.99%
TFI Allianz Polska S.A.	Polska	1,910,236	8.26%	7.03%
Allianz Polska OFE	Polska	2,132,000	9.22%	7.85%
Tadeusz Wesołowski (wraz z Augebit FIZ)	Polska	1,372,713	5.94%	5.05%
BioNTech SE	Germany	1,917,437	8.29%	7.06%
Other		8,457,612	36.59%	31.13%
Total		**23,120,148**	**100.00%**	**100.00%**

The duration of the Company is not fixed.

The calendar year is the financial year of the Company.

The core business of the Capital Company comprises research and development in biotechnology.

1.2. Going concern assumption

The Company's financial statements have been prepared on the assumption that the Company will continue as a going concern for at least 12 months after the date of signing of this financial statements.

In connection with the receiving of the financing from the European Investment Bank in the amount of EUR 22 million and the issue of series "J" shares in December 2022, the Management Board of the Company sees no threats related to the continuation of its operations and financing the development of its projects. More information on the above subject can be found in notes 19 and 31 of the financial statements.

The financial situation of the Company as at the moment of signing these financial statements is good, taking into account the current level of cash, financing received from the European Investment Bank and the issue of series "J" shares. As at December 31st 2024, the Company's cash and bonds amounted to PLN 225,400 thousand (PLN 195,963 thousand in cash in banks and PLN 25,303 thousand in low-risk investment funds and PLN 4,133 thousand in bonds). More information on the above topic can be found in notes 16, 26 and 22.9. The above funds, together with secured revenues from grants and FTE agreements, are expected, in the opinion of the Company's Management Board, to enable the achievement its objectives, including the execution of the RVU120 clinical program and the development of early-phase projects up to key data readout points. As a result of the actions taken, the Company has secured financial resources to continue its operations and planned projects to H2 2026.

1.3. Functional and reporting currency

These financial statements have been prepared in Polish Zloty (PLN). The Polish zloty is the functional and reporting currency of the company. The data in the financial statements were shown in thousands of zlotys, unless they were given with greater accuracy in specific situations.

2. International Financial Reporting Standards

2.1. Statement of compliance

These financial statements have been prepared in accordance with the requirements of the International Accounting Standard endorsed by the EU ("IFRS EU").

2.1.1. Period and scope of the report

The Company's financial statements cover the financial period from January 1, 2024 to December 31, 2024.

Status of IFRS endorsement by the EU

2.2. The following standards and interpretations were published by the International Accounting Standards Board, but are not applicable to these financial statements (i.e. financial statements for the 12-month period ended December 31, 2024).

a) Amendments to IAS 21 Effects of Changes in Foreign Exchange Rates
The published changes apply to financial statements for periods beginning on or after 1 January 2025.

b) Changes in the classification and measurement of financial instruments – Amendments to IFRS 9 and IFRS 7.
The published changes apply to financial statements for periods beginning on or after 1 January 2026.
As at the date of these financial statements, these changes have not yet been approved by the European Union.

(c) Annual amendments to IFRS
The Annual Amendments to IFRS amend IFRS 1 Application of International Financial Reporting Standards for the First Time, IFRS 7 Financial Instruments: Disclosures, IFRS 9 Financial Instruments, IFRS 10 Consolidated Financial Statements, and IAS 7 Statement of Cash Flows.
As at the date of these financial statements, these changes have not yet been approved by the European Union

d) Agreements relating to electricity dependent on natural factors: Amendments to IFRS 9 and IFRS 7.
In December 2024. The Board published amendments to help companies better capture the financial impact of contracts relating to naturally dependent electricity, which often take the form of power purchase agreements (PPAs).

(e) IFRS 18 Presentation and Disclosures in Financial Statements
In April 2024. The Governing Board published a new standard IFRS 18 "Presentation and disclosures in financial statements". The Standard is intended to replace IAS 1 – Presentation of Financial Statements and will be effective from 1 January 2027. The changes from the replaced standard mainly concern three issues: the statement of profit or loss, the required disclosures regarding performance measures, and issues related to the aggregation and disaggregation of information contained in financial statements.
The published standard will apply to financial statements for periods beginning on or after 1 January 2027.
As at the date of these financial statements, these changes have not yet been approved by the European Union

(f) IFRS 19 Non-Governmental Subsidiaries: Disclosures
In May 2024. The Board issued a new accounting standard, IFRS 19, which can be adopted by certain subsidiaries that use IFRS to improve the effectiveness of disclosures in their financial statements. The new standard introduces simplified and reduced disclosure requirements. As a result, the qualifying subsidiary applies the requirements of other IFRS accounting standards except for the disclosure requirements and instead applies the limited disclosure requirements set out in IFRS 19.
As at the date of these financial statements, these changes have not yet been approved by the European Union.

(g) IFRS 14 Regulatory Accruals
This standard allows entities that prepare financial statements in accordance with IFRS for the first time (on or after 1 January 2016) to recognize amounts arising from regulated pricing activities, in accordance with the accounting policies applied so far.
IFRS 14 will not be approved by the European Union.

h) Amendments to IFRS 10 and IAS 28 regarding the sale or contribution of assets between an investor and its associates or joint ventures. The amendments address the current inconsistency between IFRS 10 and IAS 28. Accounting treatment depends on whether the non monetary assets sold or contributed to an associate or joint venture constitute a 'business'. The changes were published on September 11, 2014. As at the date of these financial statements, the approval of this amendment is deferred by the European Union.

The Company decided not to take advantage of the possibility of early application of the above changes. As at the date of approval of these financial statements for publication, the Management Board does not expect that their introduction will have a material impact on the accounting policies

3. Summary of significant accounting policies

3.1. Going concern

The financial statements have been prepared in accordance with the historical cost concept, except for shares in Nodthera, which are measured at fair value.
The key accounting principles used by the Company have been presented below.

3.2. Revenue recognition

3.2.1. Grants

Subsidies are recognized in accordance with IAS 20. Subsidies are not recognized until there is reasonable certainty that the Company will meet the necessary conditions and will receive such subsidies. Subsidies received in the form of cash are recognized in the amount of such cash.

Government subsidies for a given cost item are recognized as revenue from subsidies systematically, for each period in which the Company recognizes expenses as costs, the compensation of which is to be a subsidy.
If the subsidy relates to an asset, then its fair value is recognized as deferred income, and then gradually, through equal annual write-offs, recognized in the income from the subsidy over the estimated useful life of the related asset.
Two types of subsidy are awarded: research subsidies and infrastructure subsidies.
In research grants, eligible costs may be the remuneration of employees related to co-financed projects, external services, depreciation of equipment, etc. Revenue from subsidies is calculated in proportion to the eligible costs incurred, the co-financing ratio in accordance with the signed grant agreement. If, under the subsidy, the Company is entitled to a bonus, e.g. due to publication of the results of work, the Management Board of the Company each time assesses whether there is reasonable certainty that the conditions for obtaining the bonus are met, and if there is such justified certainty, it recognizes the revenue from the subsidy, taking into account the Company's right.
The purchase of fixed assets is co-financed in infrastructural subsidies. Revenue from subsidies is calculated in proportion to the depreciation, co-financing rate in accordance with the signed subsidy agreement where there is reasonable assurance that grants will be received. Accrued income from subsidies is refereed to other receivables (receivables from subsidies). Cash that flows into the bank account is referred to deferred income.

3.2.2. Sales of goods and services

The Company recognizes revenues, with the exception of subsidies, in a way that presents the transaction of transfer of promised goods or services to the customer in an amount reflecting the value of the remuneration that the Company expects in exchange for these goods or services. Therefore, it is crucial to correctly determine the moment and amount of revenue recognized by the Company.
In its current research collaboration and licensing agreements, the Company licenses its intellectual property and sells services to collaborating partner entities. Revenues are generated under these agreements in the form of licensing, clinical and regulatory milestone payments, research and development services fees, and future sales-based milestones and sales-based royalties. In some cases, cooperation agreements and license agreements may also include an element of share subscription. In such a case, the Company analyzes whether the criteria for combining contracts are met.
Material ongoing collaboration and licensing agreements include royalties; milestone payments, the receipt of which is contingent upon the achievement of certain clinical, regulatory or commercial milestones; sales royalties and fees for research and development services.
The accounting policy regarding revenues from contracts for research services is described in more detail in note 5.1.

3.3. Foreign currencies

Transactions in currencies other than the functional currency (foreign currency transactions) are presented at the exchange rate ruling at the transaction date. As at the end of the reporting period, monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling as at that date. Non-monetary items measured at fair value and denominated in foreign currencies are measured at the exchange rate effective as at the date of fair value measurement. Non-monetary items are measured at historical cost.

	Balance as at 31/12/2024	Balance as at 31/12/2023
EUR / PLN	4.2730	4.3480
USD / PLN	4.1012	3.9350
GBP / PLN	5.1488	4.9997
CHF / PLN	4.5371	4.6828
JPY / PLN	2.6179	0.0277
SEK / PLN	0.3731	0.3919

3.4. Property, plant and equipment

Fixed assets, except land and the right of perpetual usufruct of land, are depreciated on a straight-line basis over the period of their estimated useful life or the shorter of the useful life or the period of the right to use the assets, which is as follows:
- building, premises, civil and water engineering structures – from 10 to 40 years;
- technical equipment and machines – 3-10 years;
- vehicles – 5 years;
- other fixed assets – 3-5 years.

4. Significant accounting judgements and estimates

When applying the accounting policies adopted by the Company, the Management Board is obliged to make estimates, judgments and assumptions regarding measurement of individual assets and liabilities. Estimates and the related assumptions are based on past experience and other factors which are considered to be material. The actual figures may be different from the adopted estimates.
The estimates and the underlying assumptions are subject to ongoing review. Changes in estimates are recognized in the period of review if they apply to that period only, or in the current and future periods if the changes apply equally to such periods.

4.1. Professional judgment in accounting

The key judgments other than those related to estimates (see Note 4.2) made by the Management Board in the process of application of the entity's accounting policies, having the most significant effect on the amounts recognized in the financial statements, are presented below.

Recognition of grants

The Company recognizes subsidy revenues from the commencement of work related to a given subsidy agreement. Due to the opinion of the Management Board that there is sufficient certainty that the Company is able to meet all the conditions resulting from the grant agreements and will not be obliged to return the received grants, grant revenues are recognized over time during the period of performance of works related to the grant.

Recognition of patents

The Company capitalizes the costs of patents that serve to protect the rights used in the course of research (not generating revenues), as well as those that generate revenues from research and development cooperation agreements. During the periodic review of the project portfolio, the Management Board makes a significant judgment related to the possibility of generating economic benefits by certain patents in the future.

Exposure to climate-related risks

The company is not exposed to climate-related risks.

4.2. Uncertainty of estimates

Presented below are the main assumptions concerning the future and other uncertainties as at the end of the reporting period, which pose a considerable risk of material adjustments to the carrying amounts of assets and liabilities in the following financial year.

4.2.1. Provisions for bonuses

Provisions for bonuses are presented in Note 23. Provisions for bonuses are estimated in accordance with the bonus model adopted by the Company, based on individual and corporate target achievement indicators. The calculated ratios are the basis for making decisions by the Management Board on the expected value of the bonus to be paid out. The Management Board takes into account many factors, including the Company's current and anticipated property and financial standing. The bonus is discretionary.

4.2.2. Useful lives of property, plant and equipment

The Company reviews the estimated useful lives of items of property, plant and equipment and intangible assets at the end of each annual reporting period. In the current financial year, the Management Board did not identify the necessity to reduce the value in use of any assets.

4.2.3. Tax settlements

Regulations regarding value added tax, corporate income tax and social security charges are subject to frequent changes. These frequent changes result in a lack of well-established benchmarks, inconsistent interpretations, and few precedents established that could apply. There are no explicit interventions clearly defining tax regulations and relations between both state authorities as well as state authorities and enterprises.

Tax settlements and other areas of activity may be subject to control by authorities that are entitled to impose penalties and fines, and any additional tax obligations resulting from the control must be paid together with interest. These conditions cause increased tax risk.

Consequently, the amounts presented and disclosed in the financial statements may change in the future as a result of the final decision of the tax inspection authority.

On July 15, 2016, the Tax Code was amended to take into account the provisions of the General Fraud Prevention Clause (GAAR). GAAR is to prevent the emergence and use of artificial legal structures created to avoid payment of tax in Poland. GAAR defines tax avoidance as an act performed primarily to achieve a tax benefit, which is in conflict with the subject and purpose of the provisions of the Tax Act. According to GAAR, this does not result in a tax benefit if the method of operation was artificial. Any occurrence of (i) unjustified division of operations, (ii) the involvement of intermediaries despite the lack of economic or economic justification, (iii) elements that mutually abolish or compensate each other, and (iv) other activities similar to those mentioned above, may be treated as a premise for existence artificial activities subject to GAAR. The new regulations will require much more judgment when assessing the tax consequences of individual transactions.

The GAAR clause should be applied to transactions made after its entry into force and to transactions that were carried out before the GAAR clause entered into force, but for which benefits were or are still being achieved after the date of entry into force of the clause. The implementation of the above provisions will enable Polish tax inspection authorities to question the legal arrangements and agreements implemented by taxpayers, such as the restructuring and reorganization of the Company.

The Company recognizes and measures current or deferred tax assets or liabilities using the requirements of IAS 12 Income tax based on profit (tax loss), tax base, unused tax losses, unused tax credits and tax rates, taking into account the uncertainty associated with settlements tax.

If, in the opinion of the Company, it is likely that the Company's approach to the tax issue or Company of tax issues will be accepted by the tax authority, the Company determines taxable income (tax loss), tax base, unused tax losses, unused tax credits and tax rates taking into account the approach to taxation planned or applied in your tax return. Assessing this probability, the Company assumes that the tax authorities authorized to audit and challenge the tax treatment will carry out such control and will have access to all information.

If the Company determines that it is not probable that the tax authority will accept the Company's approach to the tax issue or Company of tax issues, then the Company reflects the effects of uncertainty in accounting terms of tax during the period in which it determined it. The Company recognizes an income tax liability using one of the following two methods, depending on which of them better reflects the way in which uncertainty can materialize:

· The Company determines the most likely scenario - this is a single amount among the possible outcomes or

· The Company recognizes the expected value - it is the sum of probability weighted amounts among the possible results.

4.2.4. Fair value of financial instruments

The fair value of financial instruments for which there is no active market is determined using appropriate valuation techniques. When selecting the appropriate methods and assumptions, the Company is guided by professional judgment. The method of determining the fair value of individual financial instruments is presented in Note 14.

4.2.5. Impairment of trade receivables and contract assets

The company uses reserve matrices to value the write-down for expected credit losses in relation to trade receivables and assets under the contract. In order to determine the expected loan losses, trade receivables and contract assets were Companyed based on the similarity of the credit risk characteristics. The company uses its historical data on credit losses, adjusted, where appropriate, by the impact of future information.

4.2.6. Estimate for the value of Nodthera's shares

The method of determining the fair value of shares in NodThera is presented in Note 13.

4.2.7. Estimate for the employee incentive program

The method of determining the value of the employee incentive program is presented in note 28.

5. Sales revenue

5.1. Revenues

The sales revenues obtained by the Company can be divided into 2 types. The main type of contracts is the sale of R&D projects and next FTE contracts.

1. Agreements based on the FTE (Full-Time Equivalent) model

Under the contract, the Company provides appropriately qualified employees for the carry-out of research and development activities. Services in this regard may be contracted as separate agreements or as part of broader agreements, such as license sales agreements for R&D projects.

In each case, the Company identifies whether providing employees for the execution of research and development activities constitutes a separate contractual commitment from other promises within the agreement, e.g., concerning the sale of R&D projects. The Company decided that, in the agreements entered into, the provision of employees for the execution of research and development activities constitutes a series of partial services forming a single commitment to perform a service, i.e., an obligation to remain ready to execute an unspecified quantity of essentially the same services, in accordance with the scope and schedule of work determined on an ongoing basis with the client. The agreements do not specify a minimum number of hours for the involvement of the Company's employees. The level of engagement varies between periods.
To fulfill the agreement for the execution of research and development activities, subcontractors are engaged. The Company has recognized that the activities performed by subcontractors are part of the aforementioned series of partial services constituting the commitment to perform a service, and the Company acts as the principal in this regard.

The compensation for the execution of research and development activities is determined as the product of the time spent by employees on the activities during the settlement period and a fixed FTE rate covering the expected implementation costs and the assumed margin. Additionally, the Company is entitled to reimbursement of costs incurred by subcontractors. The compensation is payable in the form of periodic advances, subject to potential adjustment at the end of the settlement period. No significant financial component has been identified.

Revenue from service delivery is recognized over time. The Company is entitled to receive payment from the client corresponding directly to the value that the services performed by the Company have for the client, and therefore, revenue is recognized at the amount that the Company is entitled to invoice.

Assets related to FTE model-based agreements apply to the Company's right to receive compensation for work completed but not yet invoiced at the end of the reporting period, in part not covered by received advance payments. Meanwhile, obligations related to FTE model-based agreements concern advance payments received for the execution of work in subsequent periods. Revenue from such work is recognized within a period shorter than 12 months.

2. Sale of R&D projects

The company concludes research and development cooperation agreements. The subject of cooperation is the discovery and development of innovative small molecule compounds with potential therapeutic use in inflammatory diseases. The cooperation agreement specifies the division and scope of responsibility between the Company and the partner. At the time of signing the contract, the Company receives payment in advance, which is a remuneration for access to the existing test results. Other revenues depend on the achievement of specific scientific and clinical research progress, the success of the registration process, the so-called 'milestones', and the level of revenue from the sale of a potential drug achieved by the partner. The Company receives contractual remuneration for the defined 'milestone' achieved. In addition, the Company is guaranteed royalties on the sale of products developed as a result of cooperation.

The Company does not have sufficient information and has no influence on the pace of work performed by the project partner to be able to precisely determine when the conditions resulting in payments to the Company within the agreed, defined 'milestones' will be fulfilled, therefore the recognized revenue relates only to these revenues for which the milestone has been reached (revenue recognized in point of time). Then the recognized revenue corresponds to the remuneration for the achieved milestone.

The breakdown of the Company's sales revenues for continuing operations is as follows:

	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
Lease of employees - FTE agreements	55,985	28,470
Sale of R&D projects	21,983	18,390
Operating income	**77,968**	**46,860**

Breakdown of revenues from the sale of R&D projects is as follows:

	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
License sales	14,055	14,055
Milestone payments	7,928	4,335
Sale of R&D projects	**21,983**	**18,390**

5.2. Revenues from subsidies

	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
Infrastructure subsidies	2,394	2,692
Grants for research	21,599	17,743
	23,993	**20,436**

5.3. Geographical information

The Company operates in European Union.

Company's revenue from external customers by geographical area:

	Revenue from external customers	
	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
Poland	56	38
EU members	69,327	41,662
Other countries	8,585	5,160
Total	**77,968**	**46,860**

5.4. Operating expenses

	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
Salaries and wages	58,102	46,860
Social security charges	9,238	6,695
Other employee benefit	1,291	1,850
Employee Capital Plans	946	836
Employee benefit expense	**69,578**	**56,239**

6. Major customers

	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
Segment 1 - Innovations		
Customer A	58,433	41,346
Customer B	10,894	317
Customer C	8,585	5,160

Customers A,B- are customers for which the sales revenue exceeds 10% of segment sales revenue.

On September 14, 2023, the Company concluded an annex ("Annex") to the global license agreement of March 28, 2017 with Berlin-Chemie AG based in Berlin, Germany, part of the Menarini Group ("Menarini Group") . Pursuant to the Annex, the Company took over responsibility from the Menarini Group for conducting the phase II clinical trial MEN1703 in relapsed/refractory DLBCL, implementing this trial for the Menarini Group. The Menarini Group bears all costs related to the study, and the Company receives a full refund of the costs incurred in connection with the implementation of the clinical trial. The remaining terms of the Agreement remain unchanged, including the total payments potentially due to the Company for achieving milestones and royalties from future sales. The amount of revenue that the Company will actually receive in the future from the provision of services covered by the Annex will depend on the progress of clinical trials and the amount of work needed to implement them.

On November 29, 2022 Ryvu entered into an exclusive research collaboration and license agreement ("License Agreement") and equity investment agreement ("Investment Agreement") (together "Agreements") with BioNTech SE with its registered office in Mainz, Germany ("BioNTech"). The multi-target research collaboration will comprise several small molecule immunotherapy programs, as well as an exclusive license for Ryvu's STING agonist portfolio as standalone small molecules. The initial collaboration term is five years and can be mutually prolonged by both parties. Under the terms of the License Agreement, BioNTech paid Ryvu an upfront fee of EUR 20 million (PLN 93.626 thousand converted at the average exchange rate of the NBP for November, 29 2022, EUR 1 = PLN 4,6813) in exchange for the global, exclusive license to develop and commercialize Ryvu's STING agonist portfolio as standalone small molecules and for the right to license on an exclusive basis multiple small molecule programs ("BioNTech Exclusive Targets") as part of a multi-target research collaboration. The goal of the collaboration is generation of drug candidates to be further developed in pre-clinical studies and clinical trials, and eventually with the goal of producing an approved licensed product. Moreover, until the fifth anniversary of the effective date of this Agreement or the selection of multiple BioNTech Exclusive Targets, whichever comes first, BioNTech will have the right of the first negotiation regarding any non-partnered, immune modulation target in Ryvu's portfolio. Under the License Agreement BioNTech will fund all discovery, research and development activities under the multi-target research collaboration. Ryvu will be eligible to receive success-based development, regulatory and commercialization milestones, as well as low single-digit royalties on the annual net sales of any products that are successfully commercialized and contain a stand-alone STING compound or any compound directed to a given BioNTech Exclusive Target that is developed under the Agreement. Ryvu will be eligible to receive potential maximum milestone payments of up to EUR 876,2 million (PLN 4.101.755 thousand converted at the average exchange rate of NBP for 29, November 2022, EUR 1 = PLN 4,6813). The Management Board emphasizes that the above amount is the maximum amount possible to obtain (bio-euro value), while the amount of revenues that Ryvu will actually obtain from the Licence Agreement will depend on the progress of scientific research and clinical trials, the success of the registration process and the level of revenue from sales of the potential drugs achieved by BioNTech or its licensee. Moreover, the timeline for achieving the milestones and receiving the above potential payments are unknown at this time and not in the near future. Under the Investment Agreement BioNTech invested EUR 20 million (converted into PLN at the average exchange rate of the National Bank of Poland on the day preceding the placing by BioNTech of the subscription order in accordance with the Investment Agreement) by subscribing for new series J ordinary shares issued by the Company under the authorised capital and offered in a public offer, at a price of PLN 48.86 i.e. twenty percent (20%) premium to the volume-weighted average priceper-share (VWAP) beginning on October 26, 2022 to the day before the execution of the Agreements.

On July 6 th, 2022 the Company entered into an exclusive license agreement ("Agreement") with Exelixis, Inc. with its registered office in Alameda, California ("Exelixis"). The aim of the collaboration is to develop novel therapies utilizing Ryvu's STING (STimulator of INterferon Genes) technology. The Agreement combines Ryvu's proprietary small molecule STING agonists and STING biology know-how with Exelixis' network of expertise and resources in antibody engineering, antibody-drug conjugate (ADC) technologies, and oncology therapeutics development and commercialization experience. Exelixis will seek to incorporate Ryvu's small molecule payloads into targeted biotherapeutics such as antibody-drug conjugates. Ryvu will also provide expert guidance and know-how during the early research phase of the collaboration, and upon selection of each development candidate, Exelixis will be responsible for all development and commercialization activities. Ryvu will retain all development and commercial rights to develop its STING agonist portfolio as standalone small molecules. Under the terms of the Agreement, Exelixis paid Ryvu an upfront fee of USD 3 million (PLN 14,039 thousand at the average exchange rate of the National Bank of Poland as at July 6, 2022, 1 USD = 4.6796 PLN) in exchange for certain rights to Ryvu's STING agonist small molecules. Ryvu will also be eligible to receive research funding when the parties agree on a research plan, as well as an additional USD 3 million (PLN 14,039 thousand at the average exchange rate 1 USD = 4.6796 PLN) in near-term research-based milestones, a double-digit milestone at first development candidate selection, and additional development, regulatory and commercialization milestone payments and tiered single-to-low doubledigit royalties on the annual net sales of any products that will be successfully commercialized. In total, Ryvu is eligible to receive research, development and commercial milestones of just over USD 400 million (PLN 1,871,840 thousand at the average exchange rate 1 USD = 4.6796 PLN) for each potential product developed under this Agreement. The Company wishes to emphasize that the amount of revenue the Company will actually receive under the Agreement will depend on the progress of scientific research and clinical trials, the success of the registration process, and the level of revenues from sales of the potential drug achieved by Exelixis or its partners.

7. Financial income

	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
Financial income from financial instruments	**9,128**	**13,833**
Interest	9,128	13,833
Valuation of the option issued to the EIB*	6,849	0
Total financial revenues	**15,977**	**13,833**

*details note 19

8. Financial costs

	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
Financial costs related to financial instruments	**5,016**	**4,997**
Interest	3,808	97
Exchange differences	1,208	4,900
Total financial costs	**5,016**	**4,997**

9. Income taxes on continuing operations

9.1. Income taxes presented in the statement of comprehensive income

	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
Current income tax	297	0
Deferred income tax	0	0
Tax charge presented in the statement of comprehensive income	**297**	**0**

9.2. The effective tax rate reconciliation is as follows:

	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
Gross (Loss) before tax	**-111,138**	**-92,112**
Tax at the statutory tax rate applicable in Poland, 19% (2023: 19%)	-21,116	-17,501
Costs that do not constitute tax-deductible costs on a permanent basis	5,610	5,820
Non-taxable and tax-free income (grant income)	-4,500	-3,859
Others (e.g.: unrecognized deferred tax asset)	20,303	15,540
Tax at the effective tax rate	297	0

As at December 31, 2024, unrecognized deferred tax assets amount to PLN 67.989 thousand. Due to the history of tax losses and the lack of sufficient forecasts regarding positive tax flows, the Company did not recognize deferred tax asset.

10. Earnings per share

	Period ended 31/12/2024	Period ended 31/12/2023
	PLN per share	PLN per share
Basic earnings per share:	**(4.8)**	**(4.0)**
From continuing operations	(4.8)	(4.0)
Total basic earnings per share	(4.8)	(4.0)
Diluted earnings per share:	**(4.8)**	**(4.0)**
From continuing operations	(4.8)	(4.0)
Total diluted earnings per share	(4.8)	(4.0)

10.1. Basic earnings per share

Earnings and weighted average number of ordinary shares used for calculation of basic earnings per share:

	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
Profit/(loss) used to calculate the total basic earnings per share	-111,435	-92,112

	Period ended 31/12/2024	Period ended 31/12/2023
	quantity	quantity
Weighted average number of common shares used to calculate basic earnings per share	23,120,148	22,898,232
Weighted average number of common shares used to calculate diluted earnings per share*	23,120,148	22,898,232

The Company in statement of comprehensive income reports net loss. Therefore, in accordance with paragraphs 41 and 43 of IAS 33 potencial shares are not dilutive as their conversion would decrease loss per share from continuing operations.

11. Tangible fixed assets and rights to use

The Company reviewed the evidence of impairment of property, plant and equipment in accordance with IAS 36.12-14 and in the opinion of the Management Board, taking into account all the circumstances presented below, as at 31.12.2024 the analysis of the evidence did not indicate grounds for an impairment test and no such test was performed.
The specificity of the industry in which the Company operates is characterized by generating losses and negative cash flows during the drug discovery and development phase, up to commercialization and revenues or royalties generated from drugs that have been approved for marketing. Nor is this unexpected for a biotechnology company in phase 1 and phase 2 clinical trials.
The most important items in property, plant and equipment are new assets (including the newly built Research and Development Centre for Innovative Drugs) or almost new assets, purchased at market prices, fully used in research processes, and in the opinion of the Management Board, their fair value less selling costs is equal to or greater than their carrying amount.
The Company's capitalization as at 31.12.2024 presented a capitalization surplus over the Company's net assets of approx. PLN 746 million.

For the 2025, the Company plans to spend on non-financial non-current assets in the amount of approximately PLN 6,700 thousand.

11.1. Changes in the value of fixed assets by type in current reporting period

Item	Land	Buildings	Machinery and equipment	Vehicles	Other tangible assets (including lab equipment)	Fixed assets under construction	Rights to use other fixed assets (including laboratory equipment)	Rights to use premises	Rights to use cars	Total
Gross value as at 01.01.2024	**7,468**	**52,196**	**15,010**	**370**	**57,706**	**0**	**3,509**	**2,616**	**1,023**	**139,898**
Increases in gross value:	**0**	**16**	**733**	**0**	**1,763**	**4,605**	**1,745**	**0**	**0**	**8,861**
- Purchases	0	0	0	0	0	4,605	0	0	0	4,605
- Transfer from assets under construction	0	16	733	0	1,763	0	1,745	0	0	4,256
Decreases in gross value:	**0**	**0**	**27**	**0**	**213**	**4,256**	**0**	**0**	**0**	**4,497**
-liquidation	0	0	27	0	213	0	0	0	0	240
- Other, transfer to FA	0	0	0	0	0	4,256	0	0	0	4,256
Gross value as at 31.12.2024	**7,468**	**52,213**	**15,715**	**370**	**59,255**	**348**	**5,253**	**2,616**	**1,023**	**144,262**
Accumulated depreciation as at 01.01.2024	**0**	**6,427**	**5,078**	**47**	**44,682**	**0**	**2,891**	**2,554**	**665**	**62,344**
Inceases in accumulated depreciation:	**0**	**1,581**	**1,212**	**74**	**6,275**	**0**	**123**	**28**	**129**	**9,423**
- Depreciation / amortization write-offs	0	1,581	1,212	74	6,275	0	123	28	129	9,423
Decreases in accumulated depreciation:	**0**	**0**	**27**	**0**	**213**	**0**	**0**	**0**	**0**	**240**
- Other, liquidation	0	0	27	0	213	0	0	0	0	240
Accumulated depreciation as at 31.12.2024	**0**	**8,009**	**6,263**	**121**	**50,744**	**0**	**3,014**	**2,582**	**794**	**71,526**
Net carrying amount as at 01.01.2024	**7,468**	**45,769**	**9,932**	**323**	**13,024**	**0**	**618**	**62**	**358**	**77,555**
Net carrying amount as at 31.12.2024	**7,468**	**44,204**	**9,452**	**249**	**8,511**	**348**	**2,240**	**34**	**229**	**72,736**

11.2. Changes in the value of fixed assets by type from 01.01.2023 to 31.12.2023

Item	Land	Buildings	Machinery and equipment	Vehicles	Other tangible assets (including lab equipment)	Fixed assets under construction	Rights to use other fixed assets (including laboratory equipment)	Rights to use premises	Rights to use cars	Total
Gross value as at 01.01.2023	**7,468**	**52,146**	**13,997**	**150**	**52,666**	**0**	**4,106**	**2,531**	**1,023**	**134,088**
Increases in gross value:	**0**	**50**	**1,013**	**333**	**5,040**	**5,839**	**0**	**84**	**0**	**12,359**
- Purchases	0	0	0	0	0	5,839	0	0	0	5,839
- Transfer from assets under construction	0	50	1,013	333	4,443	0	0	0	0	5,839
- Other, changes to the contracts	0	0	0	0	0	0	0	84	0	84
- Other, shifts between categories	0	0	0	0	597	0	0	0	0	597
Decreases in gross value:	**0**	**0**	**0**	**113**	**0**	**5,839**	**597**	**0**	**0**	**6,549**
- Sale	0	0	0	113	0	0	0	0	0	113
- Other, transfer to FA	0	0	0	0	0	5,839	0	0	0	5,839
- Other, shifts between categories	0	0	0	0	0	0	597	0	0	597
Gross value as at 31.12.2023	**7,468**	**52,196**	**15,010**	**370**	**57,706**	**0**	**3,509**	**2,616**	**1,023**	**139,898**
Accumulated depreciation as at 01.01.2023	**0**	**4,848**	**3,817**	**8**	**37,408**	**0**	**2,748**	**2,525**	**514**	**51,868**
Inceases in accumulated depreciation:	**0**	**1,579**	**1,261**	**40**	**7,274**	**0**	**741**	**29**	**150**	**11,073**
- Depreciation / amortization write-offs	0	1,579	1,261	40	6,676	0	741	29	150	10,475
- Other, buyout from leasing	0	0	0	0	597	0	0	0	0	597
Decreases in accumulated depreciation:	**0**	**0**	**0**	**0**	**0**	**0**	**597**	**0**	**0**	**597**
- Other, buyout from leasing	0	0	0	0	0	0	597	0	0	597
Accumulated depreciation as at 31.12.2023	**0**	**6,427**	**5,078**	**47**	**44,682**	**0**	**2,891**	**2,554**	**665**	**62,344**
Net carrying amount as at 01.01.2023	**7,468**	**47,298**	**10,180**	**143**	**15,257**	**0**	**1,359**	**7**	**508**	**82,219**
Net carrying amount as at 31.12.2023	**7,468**	**45,769**	**9,932**	**323**	**13,024**	**0**	**618**	**62**	**358**	**77,555**

12. Intangible assets

Carrying amount	Balance as at 31/12/2024 000' PLN	Balance as at 31/12/2023 000' PLN
Patents*	5,218	4,333
Other intangible assets	2,898	1,657
Intangible assets in progress	0	347
	8,116	**6,337**

* Patents protect rights that are currently at the research level and do not generate revenue, but also those that generate revenue from partnering agreements.

12.1. Changes in the value of intangible assets by type in the current reporting period

Item	Other intangible assets	Total
Gross value as at 01.01.2024	**8,912**	**8,912**
Increases in gross value:	**2,852**	**2,852**
- Purchases	2,852	**2,852**
Gross value as at 31.12.2024	**11,764**	**11,764**
Accumulated depreciation as at 01.01.2024	**2,575**	**2,575**
Inceases in accumulated depreciation:	**1,073**	**1,073**
- Depreciation / amortization write-offs	1,073	**1,073**
Accumulated depreciation as at 31.12.2024	**3,648**	**3,648**
Net carrying amount as at 01.01.2024	**6,337**	**6,337**
Net carrying amount as at 31.12.2024	**8,116**	**8,116**

In the table above, increases relate to the acquisition of patents (PLN 804 thousand). Decreases (PLN 2.048 thousand) relate exclusively to patents. Increases in depreciation concern other intangible assets (PLN 807 thousand) and patents (PLN 266 thousand).

12.2 Changes in the value of intangible assets by type in period from 01.01.2023 to 31.12.2023

Item	Other intangible assets	Total
Gross value as at 01.01.2023	**6,415**	**6,415**
Increases in gross value:	**2,795**	**2,795**
- Purchases	2,795	2,795
Decreases in gross value:	298	298
Gross value as at 31.12.2023	**8,912**	**8,912**
accumulated depreciation 01.01.2023	**2,139**	**2,139**
Inceases in accumulated depreciation:	496	496
- Depreciation / amortization write-offs	496	496
Decreases in accumulated depreciation:	59	59
Accumulated depreciation 31.12.2023	**2,575**	**2,575**
Net carrying amount as at 01.01.2023	**4,276**	**4,276**
Net carrying amount as at 31.12.2023	**6,337**	**6,337**

13. Valuation of shares in Nodthera

As at December 31, 2024, the Company held shares in NodThera Inc., which on December 31, 2021 were exchanged for shares in NodThera Ltd in the same amount and class. NodThera Inc. is a biotechnology company developing NALP3 inhibitors in the field of inflammatory and neuroinflammatory diseases.

On September 20, 2022, NodThera Inc. Series C shares were issued (Series C Preferred Stock). The issue covered 8,698,375 shares at a price of USD 2.8741 per share, and as a result of the issue NodThera received financing in the total amount of USD 25,000,002.47. The issue was addressed only to existing investors. Series C shares are privileged similarly to series A and B shares. Ryvu did not participate in this issue.

On November 7, 2023, the shareholders of Nodthera Inc. passed a resolution enabling Nodthera Inc. to issue up to USD 20 million in aggregate of convertible promissory notes and warrants. Ryvu chose not to participate in this financing.

As at December 31, 2024, NodThera Inc. there were the following types of shares: ordinary shares and preferred shares (Junior Preferred Stock, Series A1 and A2 Preferred Stock, Series B1 and B2 Preferred Stock and Series C Preferred Stock). Ryvu is a holder of preferred shares, i.e. Junior Preferred Stock. Series A, B and C preferred shares carry the right to pay dividends and the right to non-dilution, which may be paid in the form of cash or the issue of shares of the same class. In the case of an issue of shares, shares of the same class (similarly privileged) will be acquired as shares from which the shareholder is due a dividend. For this purpose, the dividend-to-share conversion mechanism is used, according to which the total value of the dividend per share is divided by the issue (first subscription) price of shares of a given series. As a result of this calculation (the quotient of the issue price of shares of a given series and the product of: the dividend value of shares of a given series and the number of shares), the number of shares of a given class is obtained in the event of payment of the dividend through the issue of shares. In addition, in the cases specified in the agreement, preferred shares are converted into ordinary shares - in the ratio specified separately for each series of shares. In particular, the mandatory conversion of all preferred shares will take place if NodThera ordinary shares are introduced to public trading. After applying the above mechanism, i.e. calculating the dividend and converting the value of the dividend into rights to subscribe for shares as at December 31, 2024, the amount of the capitalized dividend in the form of the right to subscribe for additional shares for preferred shareholders (A1, A2, B1, B2 and C) amounts to: 11.823.227 shares.
In addition, preferred shareholders of series A and B shares were entitled to take up 1,857,064 NodThera shares under the right to non-dilution as at December 31, 2024.
The management estimated the financial impact of aformentioned convertible promissory notes and warrants, assuming the conversion price for the bonds at the level of the last issue (i.e., USD 2.8741 per share) and assuming the exercise price for the implied share price for warrants at USD 1.

Therefore, taking into account this possibility of a dividend payment and the exercise of the right to non-dilution in the form of a share issue, Ryvu's share in the share capital of NodThera would decrease from 3.1% to 2.41% on December 31, 2024.

The Management Board of Ryvu decided to include in the valuation of Ryvu's shares in NodThera a 25,5% discount (taking into account the lack of the right to dividend and the lack of the right to non-dilution) compared to the price at which they were acquired as part of the last share capital increase, i.e. through the issue of shares series C and the above approach was applied as at 31 December 2024. The discount percentage of 25,5% was calculated as the quotient of the sum of the number of shares corresponding to the capitalized dividend (i.e.: 11.088.114 shares) and the shares related to the right to non-dilution (i.e.: 1.857.064 shares) and the total number of all issued NodThera shares as at December 31, 2024 (i.e.: 59.453.801 shares).

Therefore, the share price of USD 2.2495/share was used as the basis for the valuation (share price from the last financing round, i.e. September 20, 2022, taking into account the discount corresponding to the class of shares held by the Company and impact on convertible notes and warrants). As at December 31, 2024, Ryvu held 2.41% of shares in NodThera on a fully diluted basis, and the total valuation of the Issuer's shares in NodThera Inc. amounted to PLN 16,773.742 (at the average NBP exchange rate of PLN 4,1012/USD).

Reconciliation of financial data to the carrying amount of shares in NodThera Inc included in the financial statements as at December 31, 2024.

price of new shares (in USD) from the issue of series C shares taking into account the discount corresponding to the class of shares held by the Company	2.1413
average NBP exchange rate of December 31, 2024	4.1012
new share issue price (in PLN)	8.78
number of Company's shares in Nodthera Inc.	1,910,000
value of shares in the balance sheet as at December 31, 2024 (000'PLN)	**16,774**
change in valuation - impact on the result (000'PLN)	-130

	Balance as at 31/12/2024	Balance as at 31/12/2023
Carrying amount of the Company's shares in Nodthera Inc.	16,774	16,904

Fair value of shares in Ryvu Therapeutics S.A. in NodThera Inc. was determined on the basis of other data that can be observed directly or indirectly (so-called Tier 2).

The Management Board analyzes the factors that may affect the fair value valuation of shares in NodThera on an ongoing basis by analyzing the progress of research work, assessing the Company's competitive environment, as well as the financial and liquidity situation. On this basis, the Management Board of the Company believes that the valuation of the shares held by the Company in NodThera, assuming a potential sale of shares in the future or listing of ordinary shares on the stock exchange, should be at the level of the last closed financing round (ie: September 20, 2022) with a discount for the share class held.

14. Financial assets

The table below presents the individual classes of financial assets and liabilities broken down into levels of the fair value hierarchy as at December 31, 2024. Due to the nature of these items, fair value does not differ significantly from the carrying amount. Therefore, in the columns concerning fair value as of 31.12.2024 and 31.12.2023, amounts equal to the carrying amount have been indicated.

P1 - Quotes from active markets
P2 - Significant Observable Data
P3 - Relevant data unobservable

	31/12/2024	
	carrying amount	hierarchy level
Financial assets measured at fair value:		
Financial Assets-Nodthera Shares	16,774	P2
Financial assets for which fair value is disclosed:		
Trade and other receivables	16,346	P3
Bonds	4,133	P1
Investment Funds	25,303	P2
Other financial assets (exluding bonds and Investment Funds)	36,439	P3
Financial liabilities at fair value:		
n.a.		
Financial liabilities for which fair value is disclosed:		
Liabilities from deliveries and services	33,174	P3
Investment liabilities	348	P3
Interest-bearing loans and credits	73,626	P3
Leasing liabilities	1,889	P3
Long term financial liabilities	9,228	P3

	31/12/2023	
	carrying amount	hierarchy level
Financial assets measured at fair value:		
Financial Assets-Nodthera Shares	16,904	P2
Financial assets for which fair value is disclosed:		
Trade and other receivables	9,881	P3
Bonds	11,913	P1
Other financial assets (exluding bonds)	181,300	P3
Financial liabilities at fair value:		
n.a.		
Financial liabilities for which fair value is disclosed:		
Liabilities from deliveries and services	25,064	P3
Investment liabilities	347	P3
Interest-bearing loans and credits	127	P3
Leasing liabilities	778	P3
Long term financial liabilities	8,854	P3

15. Other non-financial assets

	Balance as at 31/12/2024	Balance as at 31/12/2023
Carrying amount:	000' PLN	000' PLN
Licenses	956	608
Costs related to subsequent year	16,587	14,907
Other	674	785
	18,216	**16,300**

16. Other financial assets

Long term financial assets	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Deposits paid	19	19
Bonds	0	6,933
Bank deposits	0	10,528
	19	**17,480**

Short term financial assets	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Deposit	530	528
Bonds	4,133	4,980
Investment Funds	25,303	0
Bank deposits	35,890	170,225
	65,857	**175,733**

The maturity date of the bonds ranges from January 2025 to November 2025. The majority of the bonds have a fixed interest rate. The value of bonds based on variable interest rates was disclosed in note 22.6. The bonds held have an S&P rating from A- to A+.

The maturity date of deposits ranges from January 2025 to February 2025. All deposits have a fixed interest rate. The rating of banks in which the company holds deposits was disclosed in note 22.8.

17. Trade and other receivables

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Trade receivables	15,655	9,187
	15,655	9,187
Tax (VAT) receivables*	14,860	13,809
Other – receivables from employees, security deposits	690	695
Grants due	4,571	9,146
	35,776	**32,837**

* WHT on transactions with Biontech in the amount of PLN 9.2 million and the calculated VAT in the amount of PLN 5,6 million.

17.1. The allowance for expected credit losses on trade receivables and contract assets

In regards to trade receivables and contract assets, the Company estimated the expected credit loss as at 31 December 2024 on the basis of a provision matrix defined based on historical data concerning credit losses. It was recognised that receivables and contract assets of particular customers are characterised by a similar level of risk, they were not divided into groups.The majority of receivables were from one counterparty. As of the date of signing this Report, these receivables have been paid off.

The table below presents the calculation of expected credit losses with respect to trade receivables and contrat assets:

	Period ended 31/12/2024		
	Balance of unpaid receivables as at the balance sheet date	The rate of expected credit losses (adjusted)	The amount of the allowance for expected credit losses
Overdue	15,655	0.0001%	0
1-90 days after the deadline	0	0.0005%	0
91-180 days after the deadline	0	0.0121%	0
181-365 days after the deadline	0	0.0645%	0
More than 365 days after the deadline	0	100.0000%	0
Total	**15,656**		**0**

	Period ended 31/12/2023		
	Balance of unpaid receivables as at the balance sheet date	The rate of expected credit losses (adjusted)	The amount of the allowance for expected credit losses
Overdue	9,184	0.0000%	0
1-90 days after the deadline	2	0.0029%	0
91-180 days after the deadline	0	0.0014%	0
181-365 days after the deadline	0	0.0420%	0
More than 365 days after the deadline	0	100.0000%	0
Total	**9,187**		**0**

The average payment term for overdue receivables from the sale of goods and services in the period from January 1 to December 31, 2024 is 15 days, and in the period from January 1, 2023 to December 31, 2023, it was 11 days. Before accepting a new client, the Company assesses his creditworthiness. Due to the specific nature of its operations, the Company cooperates with entities known in the industry, which affects the assessment of credit risk. Payment terms are part of the offer presented to the contractor.

18. Share capital

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Registered share capital	9,248	9,248
	9,248	9,248

18.1. Share capital as at the end of the reporting period

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Number of shares	23,120	23,120
Par value per share	0.40	0.40
Share capital	9,248	9,248

Share capital structure as at the day of approval of financial statements i.e. 31/12/2024

Series / issue Type of shares (ordinary / registered)	Type of preference	Number of shares	Par value of series / issue
Registered “A” shares	2 votes / 1 share	4,050,000	1,620
Ordinary "B" shares	none	1,329,500	532
Ordinary "C" shares	none	1,833,000	733
Ordinary "D" shares	none	551,066	220
Ordinary "E" shares	none	2,700,000	1,080
Ordinary "F" shares	none	2,651,891	1,061
Ordinary "G1" shares	none	327,886	131
Ordinary "G2" shares	none	327,886	131
Ordinary "H" shares	none	2,200,000	880
Ordinary "I" shares	none	2,384,245	954
Ordinary "J" shares	none	4,764,674	1,906
Total		**23,120,148**	**9,248**

Share capital structure as at 31 December 2023

Series / issue Type of shares (ordinary / registered)	Type of preference	Number of shares	Par value of series / issue
Akcje serii "A" imienne	2 votes / 1 share	4,050,000	1,620
Akcje serii "B" zwykłe	none	1,329,500	532
Akcje serii "C" zwykłe	none	1,833,000	733
Akcje serii "D" zwykłe	none	551,066	220
Akcje serii "E" zwykłe	none	2,700,000	1,080
Akcje serii "F" zwykłe	none	2,651,891	1,061
Akcje serii "G1" zwykłe	none	327,886	131
Akcje serii "G2" zwykłe	none	327,886	131
Akcje serii "H" zwykłe	none	2,200,000	880
Akcje serii "I" zwykłe	none	2,384,245	954
Akcje serii "J" zwykłe	none	4,764,674	1,906
Total		**23,120,148**	**9,248**

18.2. Own shares

	Balance as at 31/12/2024	Balance as at 31/12/2023
	number of shares	number of shares
Own shares under the Incentive Scheme	1,633	8
Total	**1,633**	**8**

As at 31 December 2024, the Company holds own shares resulting from the implementation of the Incentive Scheme (see note 28). In the light of paragraph 33 of IAS 32, taking into account that the acquisition cost of these shares was PLN 0 (received free of charge by the Company as a donation from Mr Paweł Przewięźlikowski), their value as at each balance sheet date is PLN 0.

18.3. Other reserve capitals

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Others - 2015-2017 incentive program	11,172	11,172
Payments for the transfer of shares to employees	237	237
Others - incentive program 2021-2024 (i)	57,633	53,496
Valuation of options to purchase shares resulting from the investment agreement with BioNtech (ii)	1,096	1,096
Valuation of subscription warrants*	24,228	0
Valuation of put options under the agreement with the European Investment Bank*	-32,637	0
Total	**61,728**	**66,001**

(i) In 2021, the Company started the implementation of the incentive program in place in 2021-2024. Detailed information is disclosed in note 28.

(ii) The fair value of options to purchase shares is determined as at the date of concluding the agreement and is recognized as a reduction of payments from Partners for revenues recognized in accordance with IFRS 15 in correspondence with an increase in other reserves.
Summary of options data:

• date of conclusion of the contract: 29/11/2022
• option maturity date: 22/12/2022
• Number of shares: 1,917,437
• option exercise price: PLN 48.86;
• share price as at the valuation date: PLN 43.40;
• continuous dividend rate: 0%
• risk-free interest rate in continuous capitalization: 7.17%
• volatility coefficient: 50% - obtained as a standard deviation from a sample of logarithmic changes in historical share prices listed on the Warsaw Stock Exchange in the period from 16/10/2019 to the valuation date.

The fair value of options to purchase shares is determined as at the date of concluding the agreement and is recognized as a reduction of payments from Partners for revenues recognized in accordance with IFRS 15 in correspondence with an increase in other reserves.

* More details in note 19.

18.4. Share premium

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Supplementary capital created from the surplus from the issue of shares above their nominal value	159,681	159,681
including the surplus on the issue of shares above their nominal value, "H" series ordinary shares	134	134
including issue costs, "H" series ordinary shares	-4,295	-4,295
including the surplus on the issue of shares above their nominal value, "I" series ordinary shares	142,101	142,101
including issue costs, "I" series ordinary shares	-8,227	-8,227
Transfer of results from previous years in connection with the division	-10,331	-10,331
including the surplus on the issue of shares above their nominal value, "J" series ordinary shares	248,378	248,378
including issue costs, "J" series ordinary shares	-7,693	-7,693
Total Reserve Capital	**519,748**	**519,748**

19. Loans and other sources of financing

19.1. European Investment Bank Loan agreement

On August 16, 2022, the Company concluded a financing agreement with the European Investment Bank ("EIB") ("Agreement"). Under the Agreement, the EIB agreed to grant the Company a loan in the maximum amount of EUR 22,000,000.
The purpose of the Agreement is to support the development of the RVU120 molecule. The majority of the funding is used to cover costs associated with clinical trial expenses, necessary regulatory approval activities, internal research and development related to drug discovery, and costs associated with intellectual property protection.
The financing is paid in three tranches: Tranche A and B in the amount of EUR 8,000,000 each and Tranche C in the amount of EUR 6,000,000. The company is obliged to repay each of the paid tranches in one installment after 5 years from its launch. The interest rate for Tranche A is 3% per annum, for Tranche B 2.7% per annum, and for Tranche C 2.4% per annum. Interest on each tranche are payable annually.

Additional consideration for Tranche A, Tranche B and Tranche C are subscription warrants corresponding in total to 2.5% of the fully issued share capital of the Company ("Warrants"). The validity period of the Warrants is 10 years and EIB will have the right to exercise the Warrants upon the maturity of Tranche or a voluntary or mandatory prepayment event.

On May 4, 2023, the Company concluded an agreement with the European Investment Bank regarding the issue of subscription warrants to the EIB. Pursuant to the Warrant Agreement, the Company agreed to issue to EIB 592,825 subscription warrants entitling to acquire a total of 592,825 shares of the Company with a total nominal value of PLN 237,130. The exercise price of one warrant is 0.40 PLN.

On March 13, 2024, June 25, and September 5, 2024 the EIB disbursed Tranche A, B, C financing. The financing resulting from the paid tranches is included in the Company's statement of financial position as a financial liability (bank loans) measured at amortized cost. At the moment of initial recognition, the liability was recognized at fair value adjusted for direct costs of obtaining financing (commissions, fees) in the amount of PLN 70,263 thousand. At each balance sheet date, the Company determines the carrying amount (amortized cost) of the liability by applying the effective interest rate method, according to which the interest cost is calculated in a given period.

Subscription warrants issued by the Company in connection with the financing obtained under Tranche A (215,575 warrants), B (215,575 warrants) and Tranche C (161,675 warrants) meet the definition of an equity instrument within the meaning of IAS 32 and were recognized on a one-off basis in equity as at the date of payment of this tranche in the amount of PLN 24,228 thousand (note 18.3), as the difference between the amount of funds received from the EIB by the Company (PLN 94,491 thousand) and the initial fair value of the finanicial liability (PLN 70,263 thousand). Transaction costs directly related to the issue of warrants were recognized in equity.

Additionally, because the put option issued by the Company creates a contractual obligation to repurchase its own equity instruments (warrants), on the day of the disbursement of Tranches, the Company recognized in the amount of PLN 32,637 thousand (note 18.3) a liability for the amount required to settle the option, in accordance with IAS 32, offset against equity. On each reporting date after the initial recognition, the Company updates the amount of the liability for the put option, taking into account changes in the settlement price of this option, with the effects of the valuation reflected in the statement of comprehensive income. If the put option expires without being exercised by the holder (European Investment Bank), the Company will reclassify the carrying value of the liability to equity.

20. Financial liabilities

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Agreement with LLS	9,228	8,854
Option settlement liability with the EIB*	25,788	0
	35,016	**8,854**

* described in note 19. The Company recognised the option settlement liability with the EIB as a short-term financial liability due to the fact that the terms and conditions for the exercise of the option include events that are beyond the control of the Company as well as beyond the control of the EIB. However, the company does not expect the option to be exercised at least during the period until the repayment of the EIB loan.

On August 7, 2017, the Management Board of Ryvu Therapeutics S.A. (formerly Selvita S.A.) entered into an agreement with the Leukemia & Lymphoma Society (LLS) regarding cooperation in further preclinical and clinical phase I studies of the SEL120 molecule (currently RVU120) (the Agreement). Under the provisions of the Agreement, LLS has undertaken to provide the Company with financial support of up to USD 3.25 million for the RVU120 project, payable as the project develops. From the date of conclusion of the agreement to December 31, 2024, the Company has received a total of USD 2.25 million in support, which is equivalent to PLN 9.2 million (valuation at the NBP exchange rate as at December 31, 2024). At the end of 2023, the value of the support received amounted to a total of USD 2.25 million, which was the equivalent of PLN 8.9 million (valuation at the NBP exchange rate as at December 31, 2023).

In return for the financial support provided under the Agreement, LLS will be entitled, after the successful development of RVU120 and leading to the start of the III clinical phase, to receive payments for achieving milestones, and after the commercialization of RVU120 or its introduction to the market by the Company, also to royalties. The total value of payments for LLS will not exceed seven times the co-financing received under the Agreement, i.e. USD 15.75 million.

This liability was initially measured at fair value, which corresponds to the nominal amount, because the discounting effect for the 12-month period is immaterial (a 12-month period was adopted for discounting, as it cannot be assumed that the Company has control to prevent a return beyond this period. Therefore, discounting for a period longer than 12 months is not justified). After initial recognition, the liability is measured at amortized cost, which as at December 31, 2024 corresponds to the nominal value for the reasons indicated above; as a result, the liability is shown in the amount of cash received after conversion with the current PLN/USD exchange rate as at the balance sheet date.
The liability is classified as a long-term liability in each of the presented periods, because this liability is not due within 12 months from the balance sheet date, i.e. the repayment of these amounts may only take place in the event of successful development of RVU120 and the commencement of the third clinical phase (payments for milestones) and after RVU120 is commercialized or marketed by the Company (royalties), while currently RVU120 is at an early stage of development (Phase II).

On December 14, 2022, the Agreement with LLS was amended so that the maximum amount of support under the Agreement was reduced from USD 3.25 million to USD 2.25 million. At the same time, LLS undertook to participate in the public issue of series "J" Ryvu shares, which took place in December 2022 (see note 18.5), by subscribing for shares worth USD 1 million at the price determined for institutional investors in the bookbuilding process.

21. Trade and other liabilities

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Trade liabilities	31,150	23,142
Investment liabilities	348	347
Liabilities due to taxes, insurance (social security, personal income tax, PFRON)	2,226	1,962
Liabilites due to salaries and wages and other liabilities to employees	164	62
Other non-financial liabilities	1,860	1,860
Other liabilities	0	60
	35,748	**27,433**
- short-term		
Trade and other liabilities	35,748	27,433

The average payment term for purchases of goods and materials is two months. Following its due date, interest usually are not accrued on outstanding liabilities. In the case of accrual, the interest rate applicable is the same as for statutory interest.

22. Financial instruments

22.1. Capital risk management

The Company manages its capital to ensure that it will be able to continue as a going concern while maximizing its profitability through optimization of the debt to equity ratio.
The capital structure as well as the level and maturity of liabilities are reviewed on a regular basis. These reviews comprise analyses of the cost of capital and the risk associated with its individual categories.
The key items analysed by the Company are:
• cash and cash equivalents, as disclosed in Note 26,
• equity, including reserve capitals and retained earnings, as disclosed in Note 18.

The Company is not subject to any external capital requirements except for the one imposed by Article 396.1 of the Code of Commercial Companies, which the parent is obliged to comply with, whereby supplementary capital has to be created for purposes of offsetting losses. No less than 8% of the profit for the financial year has to be transferred to the supplementary capital until its value reaches at least one third of the share capital. That part of the supplementary capital (retained earnings) may not be distributed to the shareholders.

22.1.1. Net debt to equity ratio

The Company reviews its capital structure periodically. These reviews comprise analyses of the cost of capital and the risks associated with each category of capital.

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Debt (i)	-234,893	-143,610
Cash and cash equivalents	160,073	57,939
Net debt	**-74,820**	**-85,671**
Equity (ii)	143,884	259,592
Net debt to equity	**(0.52)**	**(0.33)**

(i) Debt comprises long- and short-term debt.
(ii) Equity comprises the equity presented in the statement of financial position.

The achieved level of the debt ratio is within the framework expected and accepted by the Management Board.

22.2. Categories of financial instruments

The company is exposed to risks related to financial instruments. The risks to which it is exposed are:
- market risk including currency risk and interest rate risk,
- credit risk and
- liquidity risk.

Individual types of risk are discussed in the following Notes.

22.3. Financial risk management objectives

Credit, liquidity and market risks (including mainly currency risk and interest rate risk) occur in the ordinary course of the Company's business. Financial risk management at the Company is primarily aimed to minimize the effect of market factors, such as foreign exchange and interest rates, on the key financial parameters approved in the Company's budget for the year (profit and cash flows) with the use of natural hedges.

22.4. Market risk

The Company's activities expose it to currency risk (see Note 22.5), interest rate risk (see Note 22.6) and price risk (Note 22.7). The Company does not use any derivative instruments for purposes of currency or interest rate risk management as natural hedges are sufficient to minimize the risk it is exposed to.

Exposure to all market risk categories is measured by means of a sensitivity analysis.

22.5. Foreign currency risk management

The Company enters into certain transactions denominated in foreign currencies. Hence, it is exposed to the risk of changes in foreign exchange rates. The said risk is managed by means of natural hedges.

The carrying amounts of the Company's foreign currency assets and liabilities as at the end of the reporting period:

	Liabilities		Assets	
	Balance as at 31/12/2024	Balance as at 31/12/2023	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN	000' PLN	000' PLN
EUR	82,844	6,333	107,769	59,137
USD	2,495	2,862	5,432	12,449
Other	2,825	300	298	244

22.5.1. Sensitivity to currency risk

The Company is mainly exposed to risk related to EUR and USD.

The degree of sensitivity of the Company's profit to a 15% increase and decrease of the PLN exchange rate for foreign currencies is presented in the table below. 15% is the sensitivity rate used in internal currency risk analyzes for top management and reflects management's assessment of possible changes in foreign exchange rates. The sensitivity analysis covers only unsettled monetary items denominated in foreign currencies and corrects the currency conversion at the end of the accounting period by a 15% change in exchange rates. A positive value in the table below indicates an increase in profit and an increase in equity accompanying the strengthening of the PLN exchange rate for foreign currencies by 15%. In the case of a 15% weakening of PLN against a given foreign currency, this value would be negative, and the impact on profit and equity would be the opposite.

		EUR Effect		USD Effect	
		Balance as at 31/12/2024	Balance as at 31/12/2023	Balance as at 31/12/2024	Balance as at 31/12/2023
		000' PLN	000' PLN	000' PLN	000' PLN
ASSETS					
Exchange rate increase	15%	16,165	8,871	815	1,867
Exchange rate increase	10%	10,777	5,914	543	1,245
Exchange rate increase	5%	5,388	2,957	272	622
Exchange rate decrease	-5%	-5,388	-2,957	-272	-622
Exchange rate decrease	-10%	-10,777	-5,914	-543	-1,245
Exchange rate decrease	-15%	-16,165	-8,871	-815	-1,867
LIABILITIES					
Exchange rate increase	15%	12,427	950	374	429
Exchange rate increase	10%	8,284	633	250	286
Exchange rate increase	5%	4,142	317	125	143
Exchange rate decrease	-5%	-4,142	-317	-125	-143
Exchange rate decrease	-10%	-8,284	-633	-250	-286
Exchange rate decrease	-15%	-12,427	-950	-374	-429
EFFECT ON PROFIT					
Exchange rate increase	15%	3,739	7,921	441	1,438
Exchange rate increase	10%	2,493	5,280	294	959
Exchange rate increase	5%	1,246	2,640	147	479
Exchange rate decrease	-5%	-1,246	-2,640	-147	-479
Exchange rate decrease	-10%	-2,493	-5,280	-294	-959
Exchange rate decrease	-15%	-3,739	-7,921	-441	-1,438

The Company's exposure to currency risk changes throughout the year depending on the volume of foreign currency transactions. Nevertheless, the above sensitivity analysis may be regarded as representative for determination of the currency risk exposure.

22.6. Interest rate risk management

The Company is exposed to interest rate risk resulting from floating rate lease agreements, investment loan and concluded bank deposits or purchased bonds based on variable interest rates. Hedging activities are subject to regular reviews so that they are brought into line with the current interest rate situation and predefined risk appetite, and to ensure that an optimum hedging strategy is in place.

22.6.1. Sensitivity to changes in interest rates

The sensitivity analyzes presented below are based on the degree of exposure to interest rate risk of financial instruments (liabilities arising from leasing and loan agreements) as at the balance sheet date. In the case of liabilities with a variable interest rate, it is assumed for the purposes of the analysis that the amount of unpaid liabilities at the balance sheet date was unpaid for the whole year. Internal analyzes of interest rate risk for key management members use up and down fluctuations of 50 basis points, which reflects management's assessment of the likely change in interest rates.

In the current and previous financial period, the vast majority of lease contracts were signed in EUR. In the analysis of the hypothetical impact of changes in interest rates for the balance of liabilities as at the balance sheet date, a fluctuation of 50 basis points was assumed, without taking into account the impact of restrictive clauses on negative interest rates.

31 December 2024

	< 1 year	1–2 years	2-3 years	3-4 years	4-5 years	>5 years	Total
Lease liabilities	499	740	369	281	0	0	1,889
Credit card limit used	292	0	0	0	0	0	292

31 December 2023

	< 1 year	1–2 years	2-3 years	3-4 years	4-5 years	>5 years	Total
Lease liabilities	414	165	179	21	0	0	779
Credit card limit used	127	0	0	0	0	0	127
	< 1 year	1–2 years	2-3 years	3-4 years	4-5 years	>5 years	Total
Bonds	0	1,283	0	0	0	0	1,283

The interest rate on financial instruments with a variable interest rate is updated in periods of less than one year. Interest on financial instruments with a fixed interest rate is constant throughout the period until the maturity / maturity of these instruments. Other financial instruments of the Company which are not included in the above tables are not variable interest bearing and are therefore not subject to interest rate risk.

Interest rate risk - sensitivity to changes

The table below presents the sensitivity of gross profit (loss) to reasonably possible changes in interest rates, assuming that other factors remain unchanged (in connection with liabilities with a variable interest rate). No impact on equity or total comprehensive income of the Company was presented.

	Increase / decrease by percentage points	Impact on gross profit or loss
As at 31 December 2024		
Leasing liability (EUR)		
Interest rate change	+0,5%	-4
Interest rate change	-0,5%	4
Lease liability (other currencies)		
Interest rate change	+0,5%	-2
Interest rate change	-0,5%	2
Total impact	+0,5%	-6
Interest rate change	-0,5%	6
Interest rate change		

22.7. Price risk management

The Company's exposure to equity price risk results from investments held by the Company at fair value through profit or loss (Note 13). The company owns shares in only one company, NodThera Inc. These shares have been held by the Company since the beginning of the existence of this company (i.e. 2016). NodThera's activity was based on research conducted before 2016 by the Company (then Selvita S.A.). NodThera is not listed on any stock exchange, and the increase or decrease in the value of shares in this company is, as a rule, the result of research progress. The company diversifies the price risk related to the shares in NodThera by developing its own projects, which can then be commercialized, also in a similar way as NodThera was established.

22.8. Credit risk management

Credit risk is the risk that a contracting party will default on its contractual obligations, resulting in the Company's financial losses. The Company enters into transactions only with creditworthy contracting parties. If necessary, the risk of financial losses due to default is reduced by collateral. While assessing its major customers, the Company also uses other publicly available financial information and internal transaction data. The Company's exposure to counterparty credit risk is monitored on an ongoing basis and the aggregate value of concluded transactions is distributed over approved contracting parties.

Trade receivables comprise amounts due from large, reliable and key customers operating in different geographies. Regular credit analyses are also performed considering the status of receivables.

Excludnig the Company's major customers (information on revenue has been presented in Note 6), the Company is not exposed to considerable credit risk with respect to a single counterparty. Each of these customers is an international company with a stable financial position, which considerably reduces credit risk. The concentration of credit risk with respect to other customers does not exceed 10% of gross monetary assets during the year. Data on receivables as at the balance sheet date can be found in Note 17.

Credit risk related to cash and other short-term financial assets is limited, as the Company's counterparties are banks or institutions with a high credit rating awarded by international rating agencies.

List of banks where the Company has funds on bank accounts:

Bank name	Balance as at 31/12/2024 000' PLN	Balance as at 31/12/2023 000' PLN	Rating
Bank A	84,243	123,798	BBB
Bank B	59,378	35,616	A2
Bank C	52,185	79,083	A+
Bank D	157	195	AA-
Total	**195,963**	**238,692**	

22.9. Liquidity risk management

The ultimate responsibility for liquidity risk management rests with the Management Board, which has developed a suitable management system for short-, medium- and long-term funding and liquidity requirements. The Company's liquidity management consists in ongoing monitoring of projected and actual cash flows and alignment of the maturity of financial assets with that of financial liabilities.

	As at 31/12/2024	As at 31/12/2023
Financial assets (+)	**246,175**	**269,485**
Trade receivables and subsidies	20,226	18,333
Cash	160,073	57,939
Other financial assets current	65,857	175,733
Other financial assets not-current	19	17,480
Financial liabilities (-)	**-142,029**	**-33,248**
Loan	-73,626	-127
Finance lease liabilities	-1,889	-778
Trade liabilities	-31,150	-23,142
Long term financial liabilities	-9,228	-8,854
Short term financial liabilities	-25,788	0
Investment liabilities	-348	-347
Exposure to liquidity risk	**104,146**	**236,237**

As at the balance sheet date, December 31, 2024, the company's financial liabilities were within the following maturity ranges:

Type of liability	Current:				Non-current:			Liabilities – carrying amount
	Not overdue as at 31/12/2024	within 3 months	3-12 months	Total current liabilities	1-5 years	over 5 years	Total non-current liabilities	
Loan	0	292	0	292	73,333	0	73,333	73,626
Finance lease liabilities	0	81	418	499	1,390	0	1,390	1,889
Trade liabilities	25,844	5,474	180	31,498	0	0	0	31,498
Long term financial liabilities	25,788	0	0	25,788	0	9,228	9,228	35,016
Total	**51,632**	**5,848**	**597**	**58,077**	**74,724**	**9,228**	**83,952**	**142,029**

As at the balance sheet date, December 31, 2023, the company's financial liabilities were within the following maturity ranges:

Type of liability	Current:				Non-current:			Liabilities – carrying amount
	Not overdue as at 31/12/2023	within 3 months	3-12 months	Total current liabilities	1-5 years	over 5 years	Total non-current liabilities	
Loan	0	127	0	127	0	0	0	127
Finance lease liabilities	0	414	0	414	365	0	365	778
Trade liabilities	16,919	5,458	1,113	23,489	0	0	0	23,489
Long term financial liabilities	0	0	0	0	0	8,854	8,854	8,854
Total	**16,919**	**5,999**	**1,113**	**24,030**	**365**	**8,854**	**9,218**	**33,248**

26.9.1 Available external sources of funding

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Collateralized overdraft facilities:		
Amount used	292	127
Amount available	308	473
	600	**600**

22.10. Sensitivity of the Liability from the Put Option

On each reporting date after the initial recognition, the Company updates the amount of the liability for the put option, taking into account changes in the settlement price of this option, with the effects of the valuation reflected in the statement of comprehensive income. As a result, the Company is exposed to changes in the settlement price of the option. For example, an increase in the average value of one Ryvu share by 1 PLN results in an increase in financial costs by PLN 593 thousand.

23. Accrued costs

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Unused holiday accrual	2,290	2,145
Bonuses	7,600	8,024
Liabilities due to retirement benefits	276	432
	10,166	**10,601**

24. Period occurrence and license revenues from customer contracts

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Payments from Partners (i)	55,856	66,311
Government subsidies (ii) revenues recognized in accordance with IAS 20	22,592	29,478
	78,448	**95,789**
Payments from Partners (i)		
Agreement with BioNtech, including:	40,010	55,065
- Short-term	*14,055*	*14,059*
- Long-term	*25,955*	*41,006*
	40,010	**55,065**
Others, including:	15,847	11,246
- Short-term	*15,847*	*11,246*
	15,847	**11,246**
Government subsidies (ii) revenues recognized in accordance with IAS 20		
Infrastructure subsidies, including:	19,700	20,998
- Short-term	*2,917*	*2,917*
Research subsidies, including:	2,892	8,479
- Short-term	*2,892*	*3,310*
	22,592	**29,478**

(i) Payments from partners include advance payments from contractors to cover part of the costs associated with the services performed:
- Agreement with BioNtech: The Company estimates that the entire amount of liabilities will be recognized in revenues within 5 years. The balances of liabilities arising from contracts with customers as of 31/12/2023 were settled in 2024 in the amount of PLN 14,055 thousand.
- Others: The balances of liabilities arising from contracts with customers as of 31/12/2023 were settled in 2024 in the amount of PLN 10,774 thousand.

(ii) Government subsidies include payments received resulting from subsidy contracts signed, which will be settled proportionally to the incurred costs.

25. Related party transactions

25.1. Commercial transactions

The group of related entities was determined for the purposes of preparing these condensed interim financial statements in accordance with the International Accounting Standard 24, constituting an attachment to Commission Regulation No. 1126/2008 of November 3, 2008. Personal connections based on connections between Members of the Management Board and Members of the Supervisory Board have been defined in accordance with the disposition of point 9 above International Accounting Standard 24.

Sales to related parties include rental income and re-invoicing.
Purchases from related entities include the acquisition of advisory and administrative services.

In the financial year, the Company identified the following commercial transactions with related parties. Personal connections based on connections between Members of the Management Board and Members of the Supervisory Board.

Binding type:

POA - personal relationship through shares held by the Shareholder
PORN - personal connection by a Member of the Supervisory Board

	Binding type	Sales of goods and services		Purchases of goods and services	
		Period ended 31/12/2024	Period ended 3/12/2023	Period ended 31/12/2024	Period ended 31/12/2023
		000' PLN	000' PLN	000' PLN	000' PLN
Selvita S.A.	POA	88	657	2,842	6,204
Selvita Services Sp. z o.o.	POA	0	0	-61	1,480
Ardigen S.A.	POA	0	0	336	214
Selvita Inc.	POA	0	0	2,611	3,127
Selvita d.o.o.	POA	0	0	0	0
AG Life Science Consulting GmbH & Co. KG	PORN	0	0	4	3
Scott Fields	PORN	0	0	9	28
		88	**657**	**5,741**	**11,056**

Balances at the end of the reporting period:

	Binding type	Amounts due from related parties		Amounts due to related parties	
		Balance as at 31/12/2024	Balance as at 31/12/2023	Balance as at 31/12/2024	Balance as at 31/12/2023
		000' PLN	000' PLN	000' PLN	000' PLN
Selvita S.A.	POA	0	11	1,436	1,084
Selvita Services Sp. z o.o.	POA	418	0	0	353
Ardigen S.A.	POA	0	1	22	0
Selvita Inc.	POA	0	0	160	544
Selvita d.o.o.	POA	0	0	0	0
		418	**12**	**1,618**	**1,982**

Transactions with related entities were made using market prices.

25.2 Executive compensation

Compensation of members of the Management Board and other executives in the financial year:

	Period ended 31/12/2024			Period ended 31/12/2023		
	Share based payments	Remuneration	Share-based payments*	Share based payments	Remuneration	Share-based payments*
	000' PLN	000' PLN	000' PLN	000' PLN	000' PLN	000' PLN
Management Board	**5,484**	**1,621**	**1,559**	**5,429**	**2,636**	**1,186**
Paweł Przewięźlikowski	458	0	0	450	618	0
Krzysztof Brzózka	858	467	0	841	586	96
Kamil Sitarz	635	447	427	621	562	532
Hendrik Nogai	1,731	325	375	1,762	409	312
Vatnak Vat-Ho	1,803	381	757	1,754	462	246
Supervisory Board	**1,128**	**0**	**0**	**1,160**	**0**	**0**
Piotr Romanowski	162	0	0	160	0	0
Tadeusz Wesołowski	160	0	0	157	0	0
Rafał Chwast	162	0	0	160	0	0
Axel Glasmacher	160	0	0	157	0	0
Jarl Jungnelius	1	0	0	157	0	0
Thomas Turalski	160	0	0	157	0	0
Scot Fields	164	0	0	121	0	0
Peter Smith	160	0	0	90	0	0
	6,612	**1,621**	**1,559**	**6,589**	**2,636**	**1,186**

* In accordance with IFRS2

Shares held by Members of the Management Board and Members of the Supervisory Board

	Period ended 31/12/2024		Period ended 31/12/2023	
	the number of shares	% of owned capital	the number of shares	% of owned capital
Company's management				
Paweł Przewięźlikowski	3,982,160	17.22%	4,065,036	17.58%
Krzysztof Brzózka	267,321	1.16%	267,321	1.16%
Kamil Sitarz	39,230	0.17%	39,230	0.17%
Hendrik Nogai	22,500	0.10%	13,500	0.06%
Vatnak Vat-Ho	57,000	0.25%	28,500	0.12%
Board of directors				
Piotr Romanowski	0	0.00%	50,000	0.22%
Tadeusz Wesołowski*	1,372,713	5.94%	1,372,713	5.94%
Rafał Chwast	121,115	0.52%	121,115	0.52%
Thomas Turalski	20,100	0.09%	20,100	0.09%

*directly and through Augebit FIZ

26. Cash and cash equivalents

For purposes of preparation of the statement of cash flows, cash and cash equivalents consist of cash in hand and cash at bank, including open overdraft facilities. Cash and cash equivalents at the end of the financial year, presented in the statement of cash flows, can be reconciled with the balance sheet items in the following manner:

At the balance sheet date, funds collected on bank accounts are not adjusted due to risk of impairment.

	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Cash in hand and at bank	7,030	9,562
	7,030	9,562
Cash and cash equivalents - bank deposits	153,043	48,377
	160,073	57,939

As at December 31, 2024, restricted cash amounted to PLN 2.547 thousand (prepayments from grants). As at December 31, 2023, restricted cash amounted to PLN 8.797 thousand.

27. Average headcount in the Company

	Period ended 31/12/2024	Period ended 31/12/2023
White collar employees	294	230
Total headcount	**294**	**230**

28. Share-based payments

28.1 Employee incentive program

28.1.1 Detailed description of the incentive program based on subscription warrants

On May 17, 2021, the General Meeting resolved to adopt an Incentive Scheme for employees in the form of the right to purchase shares at a preferential price. The program covers a total of 1,247,720 ordinary shares of Ryvu S.A. which will be transferred free of charge by Paweł Przewięźlikowski, owned by him and constituting a total of 25% of the Company's shares held by him. The scheme provides employees with the right to acquire shares at a preferential price of PLN 0.19 per share. Employees who have a business relationship with the company are eligible to participate in the program. The eligible persons are required to remain in a business relationship with the company and not to dispose of the shares granted under the scheme, for a period not shorter than 12 months and not longer than 36 months from the date of acquiring the shares, subject to exceptional circumstances when the employee may be released from these obligations. .

Nature of the agreement concluded with the Shareholder.

On April 20, 2021, the shareholder submitted a written declaration of will in the form of a letter of intent, in which he declares the transfer of 1,247,720 series B shares of the Issuer to the Issuer free of charge. According to the content of the letter of intent, the obligations of the Shareholder contained in the letter of intent have been effective since April 2021 and expire on the date of a) ineffective expiry of the deadline for convening the Extraordinary General Meeting of Shareholders by the Company, b) failure by the Extraordinary General Meeting of Shareholders to adopt the Incentive Scheme or c) failure to approve the list of entitled persons within 14 days from the adoption of the incentive scheme. None of the above-mentioned circumstances occurred, and the Shareholder has not yet transferred all the shares covered by the letter of intent, so the Shareholder's obligations have not expired.

On July 8, 2021, November 19, 2021, April 14, 2022, May 29, 2023, February 2, 2024, May 16, 2024 and September 24, 2024 the Shareholder concluded donation agreements with the Issuer, under which the ownership of 1,041,363 shares, 21,476 shares, 27,497 shares, 74,508 shares, 31,750 shares, 16,301 shares and 34,825 shares respectively was transferred. These shares are issued to the participants of the incentive program immediately, as a rule, on the date of their receipt by the Company.

The role of the Company.

The Management Board determines the list of persons entitled to the additional pool (as the basic pool was addressed to all employees of the Company) and the manner of determining the number of shares offered to a given participant. With regard to the Management Board, the Supervisory Board of the Company performs the same role. The Company, through its bodies, i.e. the Management Board and the Supervisory Board, exercises control over the performance of the Incentive Scheme.

Recognition of the 'donation' transaction from the Shareholder - founder of the Program.

Taking into account the specificity and legal and formal framework of the Incentive Program and IFRS standards, the Company treated the transaction of free transfer of shares ("donation") from the founder of the program, Paweł Przewięźlikowski, as a separate transaction, which in the light of par. 33 IAS 32, taking into account the acquisition cost of these shares amounting to PLN 0, was not presented in the statement of financial position and the shares received free of charge also had no impact on the statement of comprehensive income, statement of changes in equity or statement of cash flows.

28.1.2 The fair value of the share options granted during the year

The fair value of the options granted is determined as at the grant date and recognized over the vesting period in remuneration costs in correspondence with the increase in equity at the time of vesting by employees during the program period.

Summary of data about the program:

Date of granting the program ("grant date") - Phase I of the program	17.05.2021 r.
Date of granting the program ("grant date") - Phase II of the program	16.03.2022 r.
Date of granting the program ("grant date") - Phase III of the program	24.05.2023 r.
Date of granting the program ("grant date") - Phase IV of the program	11.08.2023 r.
Date of granting the program ("grant date") - Phase V of the program	29.01.2024 r.
Date of granting the program ("grant date") - Phase VI of the program	27.09.2024 r.
The maturity date of the program	26.09.2027 r.
Number of shares in the program	1.247.720
Expected number of shares after taking into account employee turnover ratio and available data as at December 31, 2024.	1,142,736

The total cost of the program was estimated on the basis of the estimated value of the shares to which employees will acquire rights during the duration of the program. The fair value of the program was determined using the Black-Scholes-Merton valuation model, taking into account the following parameters:

Program Phase	Option exercise date	Number of shares	Option exercise price (PLN))	Share price on valuation date	Continuous dividend yield	Risk-free interest rate with continuous capitalization	Coefficient of variation
I	7/9/2021	20,383	0.19	53	0%	1.96%	72%
I	7/9/2022	457,850	0.19	53	0%	1.96%	72%
I	7/9/2023	440,597	0.19	53	0%	1.96%	72%
I	7/9/2024	20,093	0.19	53	0%	1.96%	72%
I	6/30/2025	6,379	0.19	53	0%	1.96%	72%
II	3/16/2022	8,219	0.19	47.45	0%	4.82%	44%
II	3/16/2023	16,758	0.19	47.45	0%	4.82%	44%
II	3/16/2024	16,758	0.19	47.45	0%	4.82%	44%
II	3/16/2025	8,538	0.19	47.45	0%	4.82%	44%
III	5/23/2024	30,261	0.19	58.70	0%	6.04%	48%
III	5/23/2025	30,261	0.19	58.70	0%	6.04%	48%
III	5/23/2026	14,755	0.19	58.70	0%	6.04%	48%
IV	8/10/2024	2,997	0.19	58.70	0%	5.24%	47%
IV	8/10/2025	2,997	0.19	58.70	0%	5.24%	47%
IV	8/10/2026	939	0.19	58.70	0%	5.24%	47%
V	1/29/2025	17,641	0.19	54.60	0%	4.84%	47%
V	1/29/2026	3,991	0.19	54.60	0%	4.84%	47%
V	1/29/2027	3,033	0.19	54.60	0%	4.84%	47%
VI	9/26/2025	38,754	0.19	53.50	0%	4.79%	45%
VI	9/26/2027	6,782	0.19	53.50	0%	4.79%	45%

28.1.3 Estimated impact of the incentive program on the financial results (in PLN thousand):

Tranche number	Number of shares	Date of purchase of the shares	2021	2022	2023	2024	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025	2026	2027	Total discharge
Tranche No. 1	20,383	7/9/2021	1,076	-	-	-	-	-	-	-	-	-	-	1,076
Tranche No. 2	458,465	7/9/2022	13,964	10,217	-	-	-	-	-	-	-	-	-	24,181
Tranche No. 3	437,604	7/9/2023	7,649	10,144	5,328	-	-	-	-	-	-	-	-	23,120
Tranche No. 4	20,093	7/9/2024	255	304	330	173	-	-	-	-	-	-	-	1,061
Tranche No. 5	6,379	6/30/2025	56	80	80	81	20	20	-	-	40	-	-	337
Tranche No. 6	8,219	3/16/2022	-	388	-	-	-	-	-	-	-	-	-	388
Tranche No. 7	16,567	3/16/2023	-	629	164	-	-	-	-	-	-	-	-	793
Tranche No. 8	16,375	3/16/2024	-	314	389	80	-	-	-	-	-	-	-	784
Tranche No. 9	8,155	3/16/2025	-	107	130	129	26	-	-	-	26	-	-	392
Tranche No. 10	30,261	5/23/2024	-	-	1,072	699	-	-	-	-	-	-	-	1,771
Tranche No. 11	30,261	5/23/2025	-	-	536	888	218	129	-	-	347	-	-	1,771
Tranche No. 12	14,755	5/23/2026	-	-	174	289	71	72	73	73	288	113	-	864
Tranche No. 13	2,997	8/10/2024	-	-	68	107	-	-	-	-	-	-	-	175
Tranche No. 14	2,997	8/10/2024	-	-	34	88	22	22	10	-	53	-	-	175
Tranche No. 15	939	8/10/2024	-	-	7	18	5	5	5	5	18	11	-	55
Tranche No. 16	17,641	1/28/2025	-	-	-	884	76	-	-	-	76	-	-	960
Tranche No. 17	3,991	1/28/2026	-	-	-	100	27	27	27	27	109	9	-	217
Tranche No. 18	3,033	1/28/2027	-	-	-	51	14	14	14	14	55	55	4	165
Tranche No. 19	37,122	9/26/2025	-	-	-	521	488	493	477	-	1,459	-	-	1,979
Tranche No. 20	6,496	9/26/2026	-	-	-	30	28	29	29	29	115	115	85	346
Total	**1,142,736**		**22,999**	**22,184**	**8,313**	**4,137**	995	810	635	148	**2,587**	**303**	**89**	**60,613**

The valuation of the program, regarding shares currently issued to employees as of December 31, 2024, showed its total estimated cost at PLN 60.613 thousand, which is included in the Company's costs starting from the second quarter of 2021 until the second quarter of 2027.

29. Contingent liabilities and contingent assets

29.1. Contingent liabilities

In the periods covered by the financial statements, the Company incurred contingent liabilities necessary to receive the subsidy and the loan taken out.
Contingent liabilities include:
- promissory note liabilities - covering the amount of subsidies received for which the durability periods have not yet expired, together with interest in the amount specified as for tax arrears calculated from the date of transfer of funds for the account to the date of return. In the period covered by the report, the amount of PLN 20.585 thousand was credited to bank accounts for the co-financing. As at the balance sheet date, December 31, 2024, the sum of cash received from subsidies, whose durability period has not yet expired, is PLN 171.637 thousand.

- claims - in connection with the performance of the contract for the performance of construction works as part of the general contracting of the investment entitled: "Construction of the Research and Development Center for Innovative Medicines Selvita S.A." the contractor, i.e.: Mota-Engil Central Europe S.A., pursues claims for costs incurred in connection with the prolonged implementation of the Agreement, the unpaid part of the lump sum remuneration, as well as supplementary remuneration for additional, replacement and omitted works (PLN 5,391,425.63) and claims resulting from unauthorized - in the opinion of the contractor - use by the Company of the guarantee of proper performance of the contract and removal of defects and faults (PLN 2,063,507.56). Together with statutory interest, the Contractor demands from the Company the total amount of PLN 7,671,285. The lawsuit was delivered to the Company on January 19, 2022. The Company believes that the claim is completely groundless, therefore it did not create a provision.

29.2. Contingent assets

In connection with the implementation of the contract for the performance of construction works as part of the general contracting of the investment entitled: "Construction of the Research and Development Center for Innovative Medicines Selvita S.A." The company is pursuing claims from Mota-Engil Central Europe S.A. for the payment of PLN 13,756,717.07. The lawsuit was filed on September 24, 2021.

30. Significant events of the reporting period

On February 3, 2024, the Company received information about achieving the second milestone in the project implemented jointly with the American company Exelixis Inc. with its registered office in Alameda, California, under the license agreement of July 6, 2022 (described in note 6). In accordance with the Agreement, for achieving the second milestone, Ryvu is entitled to receive a payment from Exelixis in the amount of USD 2 million (which is the equivalent of PLN 7,928,200 converted at the average NBP exchange rate of February 2, 2024, 1 USD = 3.9641 PLN).

31. Significant events after the balance sheet date

Termination of STING program under Research Collaboration Option and Exclusive License Agreement with BioNTech SE

On January 29, 2025, BioNTech SE, notified the Company that for reasons relating to change of BioNTech’s portfolio strategy, the collaborator has decided to exercise its right to terminate the STING program covering Ryvu’s STING agonist portfolio as standalone small molecules along with two other of several previously undisclosed programs, which were implemented under the research collaboration and exclusive license agreement dated November 29, 2022

Strategic reorganization

The Management Board of the Company informed on February 25, 2025 about the adoption of the rules of the Collective Redundancy specifying the rules of conduct in matters concerning the employees affected by the intended Collective Redundancy and about the decision of the Management Board of the Company to carry out the Collective Redundancy on the terms set out in the established rules. The Collective Redundancy will be carried out as of February 25, 2025 to June 30, 2025 and will affect approximately 30% (no more than 95) employees of the Company. As a result of Collective Redundancy, the Company will still employ approximately 200 employees, retaining its full potential to develop the projects. The estimated costs for severance payments for dismissed employees amount to PLN 2,000 thousand.

32. Notes to the cash flow statement

Explanation of the reasons for significant differences between changes in certain items in the balance sheet and changes in the same items disclosed in the cash flow statement:

	Period ended 31/12/2024	Period ended 31/12/2023
	000' PLN	000' PLN
The change in liabilities, excluding credits and loans, results from the following items:	**-9,749**	**9,907**
Change in liabilities resulting from the balance sheet	-2,603	9,851
Adjustment for the change in liabilities resulting from the acquisition of tangible fixed assets	-1	56
Adjustment for put option valuation	-6,849	0
Other	-296	0

33. Remuneration of the entity authorized to audit financial statements

Itemization	Balance as at 31/12/2024	Balance as at 31/12/2023
	000' PLN	000' PLN
Mandatory audit of the annual financial statements and mid-year review	163	220
Mid-year review	92	78
Other certification services	31	41
Total salary	**286**	**339**

34. Revenues and costs of R&D own services

Wyszczególnienie	Balance as at 31/12/2024	Balance as at 31/12/2023	Year-over-year change
	000' PLN	000' PLN	000' PLN
Net revenues from the sale of research and development services	77,968	46,860	31,108
Research and development expenses	-219,601	-156,728	-62,873
Employment in jobs related to research and development work	306	256	50

35. Approval of the financial statements

The financial statements were approved by the Company's Management Board on March 11, 2025.

Dokument podpisany przez Bartłomiej Konicki
Data: 2025.03.11 10:19:13 CET

Prepared by: Bartłomiej Konicki

Signatures of members of the Management Board:

Dokument podpisany przez Paweł Tadeusz Przewięźlikowski
Data: 2025.03.11 13:15:10 CET

Paweł Przewięźlikowski - President of the Board

Dokument podpisany przez Krzysztof Daniel Brzózka
Data: 2025.03.11 12:32:29 CET

Krzysztof Brzózka - V-ce President od the Board

Dokument podpisany przez Kamil Sebastian Sitarz
Data: 2025.03.11 11:03:29 CET

Kamil Sitarz - Member of the Board

Digitally signed by Vatnak Vat-Ho
Date: 2025.03.11 07:35:07 MDT

Vatnak Vat-Ho - Member of the Board

Digitally signed by FRANZ HENDRIK DR. NOGAI
Date: 2025.03.11 13:59:29 CET

Hendrik Nogai - Member of the Board

CONTACT

RYVU THERAPEUTICS

Leona Henryka Sternbacha 2

30-394 Krakow, Poland

Tel: +48 12 314 02 00

GENERAL INQUIRIES

ryvu@ryvu.com

RYVU THERAPEUTICS